Developing Oral mRNA Vaccines!

Article source: Medicine Cube Pro

Author: Bai Lu

On April 11, BioNTech announced an exclusive collaboration with Matinas BioPharma to combine BioNTech's mRNA vaccine development expertise and Matinas' Lipid Nanocrystal (LNC) delivery platform technology to advance the development of new dosage forms of mRNA vaccines, including A potential formulation for an oral vaccine

Headquartered in New Jersey, USA, Matinas has been operating since 2013 and is focused on redefining the intracellular delivery of nucleic acids and small molecules using its LNC platform technology

Drug molecules are encapsulated in this layered design, protecting them from harsh environmental conditions or enzymes before entering target cells

To date, the platform has been validated in multiple preclinical studies and is protected by a robust IP portfolio

Preclinical and clinical data suggest that this new technology can provide a solution for safe and effective intracellular delivery of small molecules and larger, more complex molecules such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines

Matinas' drug candidates from the LNC platform include: 1) MAT2203, an oral formulation of amphotericin B for the treatment of severe invasive fungal infections (IFI); 2) an oral amikacin for the treatment of non-tuberculous mycobacteria (NTM) Formulation MAT2501; 3) Lead product candidate LYPDISO™ (MAT9001) has the potential to be the best-in-class omega-3 fatty acid therapy for cardiovascular and metabolic diseases

Note: The original text has been deleted

References:

BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines (Source: BioNtech official website)